Sanofi says EU approves Cenrifki for non-relapsing secondary progressive multiple sclerosis

• European Commission cleared Sanofi’s Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses in the past two years.
• Sanofi positioned Cenrifki as the first EU medicine targeting disability progression in non-relapsing SPMS.
• Decision relied on Phase 3 HERCULES data, supported by GEMINI 1 and 2 studies in relapsing multiple sclerosis.
• Sanofi plans a Germany launch this year, backed by a risk-management program focused on liver monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230100PRIMZONEFULLFEED1001209040) on June 23, 2026, and is solely responsible for the information contained therein.